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The traditional bare-metal stent (BMS) was initially widely used, with considerable efficacy and safety. However, longterm outcome and restenosis rate has been very discouraging. 3 Recently, sirolimus-eluting stents (SES) have been increasingly used for treating restenosis after having used BMS, as well as for treating the native coronary narrowing. [4] [5] [6] [7] For coronary arterial disease (CAD) patients with diabetes, the outcome, efficacy and safety of SES and BMS remain controversial, [8] [9] [10] [11] [12] [13] [14] [15] [16] mainly due to small sample sizes or low statistical power. Meta-analysis, combining results of several studies and producing a single estimate of major events with enhanced precision, has been considered a powerful tool for summarising inconsistent results from different studies. [17] [18] [19] [20] Heterogeneity and publication bias can be detected with funnel plots and other methodologies. [21] [22] [23] [24] [25] [26] To clarify this controversy, in this study, we performed a meta-analysis and subgroup analysis, along with heterogeneity and publication-bias analysis, and compared the major cardiac events, target-lesion revascularisation, myocardial infarction and mortality rate in CAD patients with diabetes who were treated with SES or BMS.
Statistical analysis
Analysis was performed with software review manager 5.1 (Cochrane collaboration, http://ims.cochrane.org/revman) and comprehensive meta-analysis (Englewood, NJ); p < 0.05 was regarded as statistically significant. Meta-analysis was performed in fixed-or random-effect models.
Odds ratios (OR) and 95% confidence intervals (CI) were estimated in each study. Pooled ORs were obtained using the Mantel-Haenszel method in a fixed-effect model, and the DerSimonian-Laid method in a random-effects model. 24 The significance of pooled ORs was determined by the Z-test. Cochrane's Q-statistic was used to assess within-and betweenstudies variations. A p < 0.10 on the Q-statistic was regarded as heterogeneity across the studies. I 2 was also used to test heterogeneity with the formula:
where I 2 < 25% means no heterogeneity; I 2 = 25-50% means moderate heterogeneity; I 2 > 50% means large or extreme heterogeneity. 27 The random-effects model was also used for evaluating the possibility of heterogeneity of studies. Publication bias was evaluated with Egger's test and funnel plots, 28 which compensate for each other's drawbacks. If there is evidence of publication bias, the funnel plot is noticeably asymmetric. For the Egger's test the significance level was set at 0.05. Sensitivity analysis was also performed to test reliability of the results, by removing one study at a time and repeating the meta-analysis.
results
As shown in Fig. 1 
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The efficacy of SES versus BMS is presented in Table 2 . As shown, the pooled OR was 0.42 (95% CI: 0.24-0.74, p < 0.01) for SES versus BMS. This suggests that, after the data had been pooled, SES were more effective than BMS in CAD patients with diabetes. However, there was publication bias (t = -4.19, p < 0.05).
As shown in Fig. 2A , the pooled OR was 0.42 (95% CI: 0.24-0.74, p < 0.01) for overall events, suggesting that SES had a better outcome compared with BMS, with a greater reduction in risk for major cardiac events. However, there were heterogeneities between the studies (Q 2 = 20.14, I 2 = 75.0%, p < 0.1) and publication bias, as shown in Fig. 2B (asymmetric funnel plot). This was further confirmed with Egger's linear regression test, shown in Table 2 (t = -4.19, p < 0.05).
As shown in Fig. 3 , the pooled OR was 0.26 (95% CI: 0.11-0.59, p < 0.01) for SES versus BMS, suggesting that SES had a better revascularisation rate for target lesions compared with BMS. However, there were heterogeneities between the studies (Q 2 = 24.44, I 2 = 80.0%, p < 0.1) and publication bias (t = -6.44, p < 0.05).
As shown in Fig. 4 , the pooled OR was 0.92 (95% CI: 0.61-1.40, p > 0.05) for SES versus BMS, suggesting that the overall risk for myocardial infarction was not significantly different between these two groups. There was no heterogeneity between the studies (Q 2 = 4.37, I 2 = 0%, p > 0.1) but there was publication bias (t = -3.44, p < 0.05).
As shown in Fig. 5 , the pooled OR was 1.19 (95% CI: 0.74-1.92, p > 0.05) for SES versus BMS, suggesting that the overall risk of mortality was not significantly different between the groups. There was no publication bias (t = -1.69, P > 0.05) or heterogeneities between the studies (Q 2 = 3.88,
Subgroup analyses were stratified by sample size, subjects' geographical area and study method. As shown in Table 2 and Figure 6A -C, the pooled OR was 0.28 (95% CI: 0.16-0.48, p < 0.01, Fig. 6A 
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Odds 6C ) in studies whose method of study was non-RCT, without heterogeneities between the studies (Q 2 = 0.92, I 2 = 0%, p > 0.1). By removing one study at a time, a sensitivity analysis was performed and the model was rerun to determine the effect on each estimate. It showed that the above meta-analysis estimates did not change significantly after removal of each study, implying that these results were statistically reliable.
discussion
A growing number of studies has shown the efficacy and safety of SES versus BMS for treating CAD patients with diabetes, 9, 29 but the outcome has been controversial. In this analysis, we retrieved six studies, which included 1 259 CAD subjects with diabetes, and performed a meta-analysis. It showed that the SES group had a significant reduction in major adverse cardiac events, as well as target-lesion revascularisations, compared with the BMS group. There was no significant difference for myocardial infarction or mortality.
These results are consistent with a recent study that suggested a significant reduction in target-vessel revascularisations with SES, but with similar mortality rates. 9 Unlike this study, in which the incidence of myocardial infarction was higher, our analysis showed no difference for myocardial infarctions between the groups.
Another recent study conducted in Europeans confirmed the efficacy of SES compared with BMS, along with comparable mortality rates and myocardial infarctions, 11 which further proved the validity of our analysis. The efficacy and safety of SES have been receiving more and more supportive reports. [30] [31] [32] [33] The uniqueness of our analysis and findings is that it proved the efficacy and safety of SES in CAD patients with diabetes.
Heterogeneity is one major concern with regard to the validity of meta-analyses. 26, 34 Non-homogeneous data can easily give misleading results. In our study, the Q and I 2 statistics were performed to test heterogeneity. For all samples, there was significant heterogeneity for major adverse cardiac events in the SES and BMS groups.
We further conducted subgroup analysis according to sample size, ethnicity and study method. It demonstrated that in the studies where sample size was ≤ 90, method was a RCT and population was European, the overall major cardiac events were significantly different between the SES and BMS groups. Heterogeneity between the studies was decreased after stratifying the samples. No significant heterogeneity was observed with RCTs, suggesting an RCT is important for good results. More high-quality RCTs are therefore warranted.
Another concern for meta-analyses is publication bias, due to selection of the studies included. In this study, using funnel plots and Egger's test, 28, 35, 36 we found publication bias for overall major cardiac events, target-lesion revascularisations and myocardial infarction, but not for overall mortality. Furthermore, the sensitivity analysis confirmed there was no change if one study was removed at a time. Although more studies would have produced better results, overall, our results were statistically reliable.
Conclusion
This meta-analysis suggested that, compared with BMS, SES are more effective and safer for reducing major cardiac events in CAD patients with diabetes. This may indicate the direction for future trials and clinical implementation.
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